#2885 DYNAMICS OF URINARY SYNDROME IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS DEPENDING ON THE USE OF ANTICOAGULANT

Abstract Background and Aims to study the dynamics of urinary syndrome in patients with chronic glomerulonephritis (CGN) against background use rivoroxaban. Method 108 (CGN), on 3-month basic therapy inclusion anticoagulant rivaroxaban 55 without 53 patient. Initially after 3 months, composition sediment was assessed. Results Patients CGN had significant proteinuria (3.23±0.12g/l versus 0.01±0.004 control group (CG), p<0.001), hematuria (42.58±2.10 erythrocytes field vision, 0.75±0.25 cells leukocyturia (38.25±0.80 leukocytes 1.70±0.24 view CG, p<0.001) cylindruria (38.11±1.04 cylinders view, 0.10±0.07 p<0.001). Albuminuria contributed an increase specific gravity urine (1021.64±0.44 g/l 1017.45±0.65g/l By end hospitalization period, there a improvement syndrome: relative indicators more than 30%. Thus, degree decreased 1.98± 0.10 (p<0.001 reliability difference initial data), – 26.38±1.43 vision (p<0.001), 22.04±0.88 25.45±0.79 (p<0.001). Against decrease diuretic therapy, density by 0.73% (up 1014.15 ± 0.45g/l, baseline data - p <0.001). Conclusion Rivaroxaban is effective oral anticoagulant, long–term which as part safe, well tolerated pathogenetically justified. The associated achievement favorable values proteinuria, 3rd month therapy.